Results 111 to 120 of about 1,188 (167)

Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review. [PDF]

Eur J Health Econ
Xander NSH, Belleman T, Salcher-Konrad M, Hendrickx A, Chen J, Klein Gebbink AS, Schneider P, Morgan K, Groene O, Durand-Zaleski I, Thielen FW, Uyl-de Groot CA.   +11 more
europepmc   +1 more source

Examining confidential wholesale margin estimates in European countries for the price negotiation of patented drugs in Germany: a statistical model. [PDF]

Health Econ Rev
An der Heiden I, Schiffhorst G, Müller L, Albrecht M, Bartol A, Wiberny S.   +5 more
europepmc   +1 more source

DDD-costs have a strong influence on antibacterial drug prescription in Germany: a differentiated correlation analysis from 1985 to 2022. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Bindel LJ, Seifert R.
europepmc   +1 more source

New drugs and their performance 10 years after approval: a systematic analysis. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Manfouo B, Seifert R.
europepmc   +1 more source

Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Bindel LJ, Seifert R.
europepmc   +1 more source

Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action. [PDF]

Curr Oncol
Sehdev S, Gotfrit J, Elias M, Stein BD.
europepmc   +1 more source

National guidelines for gastric cancer: redundant or needed? [PDF]

Gastric Cancer
Lordick F, Wörmann B.
europepmc   +1 more source

Towards a Unified European View of Clinical Evidence: What 'Health Technology Assessment Organizations' Can Learn from Regulatory Experience. [PDF]

J Mark Access Health Policy
Broich K, Löbker W.
europepmc   +1 more source